ABSTRACT
An 8-year-old male neutered French Bulldog was referred for continued nasal dyspnea following a staphylectomy revision performed one month prior to presentation. The patient had a prior history of skin allergies and underwent brachycephalic airway surgery performed at one year of age. Computed tomography (CT) revealed an osseous-encased, cystic mass arising from the right maxillary sinus. Surgical biopsies were performed and a mucocele with sinusitis and glandular hyperplasia was diagnosed. Based on our systematic review of the literature, maxillary sinus mucocele has not been reported in the dog and should be among the differentials for sinus cystic masses.
Subject(s)
Dog Diseases , Dogs , Mucocele , Paranasal Sinus Diseases , Animals , Male , Bone and Bones/pathology , Dog Diseases/diagnostic imaging , Dog Diseases/surgery , Dog Diseases/pathology , Maxillary Sinus/diagnostic imaging , Maxillary Sinus/surgery , Maxillary Sinus/pathology , Mucocele/diagnostic imaging , Mucocele/surgery , Mucocele/veterinary , Paranasal Sinus Diseases/diagnostic imaging , Paranasal Sinus Diseases/surgery , Paranasal Sinus Diseases/veterinary , Tomography, X-Ray Computed/veterinaryABSTRACT
BACKGROUND: Neutropenia is an adverse effect of vincristine when used in multidrug chemotherapy protocols. OBJECTIVE: To determine the incidence of neutropenia, identify potential risk factors for neutropenia, and determine the effect of neutropenia on outcome, in dogs receiving vincristine for treatment of immune-mediated thrombocytopenia (ITP). ANIMALS: One hundred twenty-seven client-owned dogs presumptively diagnosed with ITP. METHODS: In this retrospective cohort study, medical records were reviewed to identify dogs presumptively diagnosed with ITP, and treated with vincristine, over a 15-year period. Logistic regression was used to identify risk factors for the development of neutropenia in dogs receiving vincristine. Time to platelet count ≥40 000 platelets/µL, survival, and duration of hospitalization were compared between neutropenic and non-neutropenic dogs. RESULTS: Vincristine was administered to 127 dogs with presumptive ITP; 19 became neutropenic. Administration of cyclosporine was significantly (P < .001) associated with the development of neutropenia (odds ratio: 12.97, 95% confidence interval: 4.17, 40.35). There was no difference in median time to ≥40 000 platelets/µL between neutropenic dogs (4 days; range, 1-14 days) and non-neutropenic dogs (3 days; range, 0-48 days). Percentage survival to discharge was 95% in both groups, but median duration of hospitalization was significantly longer in neutropenic dogs (6 days; range, 3-22 days) compared to non-neutropenic dogs (4 days; range, 2-15 days). CONCLUSIONS AND CLINICAL IMPORTANCE: Cyclosporine administration was associated with the development of neutropenia in dogs receiving vincristine, which might be related to effects on metabolism of vincristine. Neutrophil counts should be monitored in dogs receiving vincristine treatment for ITP, particularly if administered in conjunction with cyclosporine.
